REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $5K invested in REGENERX BIOPHARMACEUTICALS in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and closing their positions.
150% more capital invested
Capital invested by funds: $2K → $5K (+$3K)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$3K |
Top Sellers
RGN Hedge Fund Activity: Q2 2022 in Review
2 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q2 2022, worth a combined $5K — up 150% from $2K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RGN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was MAI Capital Management, opening a new position worth an estimated $3K.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q2 2022, up from 1 in Q1 2022.
- Funds reported $5K of REGENERX BIOPHARMACEUTICALS stock for Q2 2022, up 150% quarter-over-quarter.
- 1 fund opened new REGENERX BIOPHARMACEUTICALS positions in Q2 2022 and 0 closed out, a net change of +1 holder.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q2 2022 was MAI Capital Management, an estimated $3K added.
Based on aggregated 13F filings for Q2 2022.